Eric R Siemers

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease
    Kazunori Uenaka
    Lilly Research Laboratories Japan, Eli Lilly Japan K K, Sannomiya Plaza Bldg 7 1 5, Isogamidori, Chuo Ku, Kobe 651 0086, Japan
    Clin Neuropharmacol 35:25-9. 2012
  2. ncbi Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase
    Eric R Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
    Clin Neuropharmacol 30:317-25. 2007
  3. doi Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
    David B Henley
    Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer s Team, DC 6161, Indianapolis, IN 46285 6161, USA
    Expert Opin Pharmacother 10:1657-64. 2009
  4. doi Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
    Eric R Siemers
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 33:67-73. 2010
  5. doi Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia
    Peng Yu
    Eli Lilly and Company, Indianapolis, IN, USA
    J Alzheimers Dis 32:373-85. 2012
  6. ncbi New pathways in drug discovery for Alzheimer's disease
    Eric R Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Neurol Neurosci Rep 6:372-8. 2006
  7. doi Commentary on "a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium"
    Eric R Siemers
    Eli Lilly and Company, Indianapolis, IN, USA
    Alzheimers Dement 4:171-3. 2008
  8. ncbi Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry
    Tomoyuki Oe
    Centers for Cancer Pharmacology and Excellence in Environmental Toxicology, Departments of Pharmacology and Chemistry, University of Pennsylvania, Philadelphia, PA 19104 6160, USA
    Rapid Commun Mass Spectrom 20:3723-35. 2006
  9. ncbi Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry
    Valentina Gelfanova
    Integrative Biology Division, Lilly Research Laboratories, Greenfield, IN 46140, USA
    Brief Funct Genomic Proteomic 6:149-58. 2007
  10. pmc Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease
    Adam S Fleisher
    University of California, San Diego, La Jolla, CA 92037, USA
    Arch Neurol 65:1031-8. 2008

Collaborators

Detail Information

Publications13

  1. doi Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease
    Kazunori Uenaka
    Lilly Research Laboratories Japan, Eli Lilly Japan K K, Sannomiya Plaza Bldg 7 1 5, Isogamidori, Chuo Ku, Kobe 651 0086, Japan
    Clin Neuropharmacol 35:25-9. 2012
    ..Pharmacokinetics (PK), pharmacodynamics, safety, and tolerability after a single dose of solanezumab were compared between Japanese and white patients with AD...
  2. ncbi Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase
    Eric R Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
    Clin Neuropharmacol 30:317-25. 2007
    ..gamma-Secretase inhibitors may be useful as disease-modifying drugs for the treatment of Alzheimer disease. LY450139 is a gamma-secretase inhibitor currently in clinical development, with doses being optimized through the use of biomarkers...
  3. doi Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
    David B Henley
    Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer s Team, DC 6161, Indianapolis, IN 46285 6161, USA
    Expert Opin Pharmacother 10:1657-64. 2009
    ..Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit...
  4. doi Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
    Eric R Siemers
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 33:67-73. 2010
    ..LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD...
  5. doi Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia
    Peng Yu
    Eli Lilly and Company, Indianapolis, IN, USA
    J Alzheimers Dis 32:373-85. 2012
    ..Overall, the combination of MRI, ApoE, and cognitive scores provided the best trade-off between cost and time compared with other biomarker combinations for patient recruitment in clinical trial...
  6. ncbi New pathways in drug discovery for Alzheimer's disease
    Eric R Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Neurol Neurosci Rep 6:372-8. 2006
    ....
  7. doi Commentary on "a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium"
    Eric R Siemers
    Eli Lilly and Company, Indianapolis, IN, USA
    Alzheimers Dement 4:171-3. 2008
  8. ncbi Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry
    Tomoyuki Oe
    Centers for Cancer Pharmacology and Excellence in Environmental Toxicology, Departments of Pharmacology and Chemistry, University of Pennsylvania, Philadelphia, PA 19104 6160, USA
    Rapid Commun Mass Spectrom 20:3723-35. 2006
    ..Moreover, the introduction of stable isotope labeled internal standards offers the potential to achieve a more rigorous account of the influence of methodological effects related to sample collection and processing...
  9. ncbi Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry
    Valentina Gelfanova
    Integrative Biology Division, Lilly Research Laboratories, Greenfield, IN 46140, USA
    Brief Funct Genomic Proteomic 6:149-58. 2007
    ..Application of the MALDI-Tof assay to CSF obtained from healthy volunteers and Alzheimer's disease patients indicated statistically significant 43% lower levels of Abeta(1-42) in the AD group (P = 0.0025)...
  10. pmc Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease
    Adam S Fleisher
    University of California, San Diego, La Jolla, CA 92037, USA
    Arch Neurol 65:1031-8. 2008
    ..To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease...
  11. doi Partnership between academia and industry for drug discovery in Alzheimer's disease
    Adrian J Ivinson
    Harvard NeuroDiscovery Center, Harvard Medical School, Boston, MA, USA
    Alzheimers Dement 4:80-8. 2008
    ....
  12. ncbi Neuropsychological test performance in healthy volunteers before and after donepezil administration
    Leigh J Beglinger
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Psychopharmacol 18:102-8. 2004
    ..While the results are counter to expectations, some tests in the battery did detect a cognitive change (transient mild worsening during drug administration) in healthy volunteers...
  13. ncbi Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease
    Brandy Matthews
    Indiana University School of Medicine, Department of Neurology, Indianapolis, IN, USA
    Am J Geriatr Psychiatry 11:146-59. 2003
    ..An understanding of the relationship between a statistically significant effect size in an imaging marker and a clinically significant change in rate of disease progression will require additional studies...